Literature DB >> 30612309

Human antigen R and drug resistance in tumors.

Fenghai Zhou1, Fa Zhang2, Chuan Zhou3, Mengtian Liang2, Zhonglin Cai4, Haidi Lv2, Wenjuan Li2, Xupan Wei2.   

Abstract

The human embryonic lethal abnormal visual protein, HuR, belongs to the Hu family of RNA-binding proteins. Over the past two decades, HuR has been extensively associated with multiple biological characteristics of tumors, including tumor development and progression, angiogenesis, invasion, migration and prognosis, since this protein regulates the stability of cancer-associated target mRNAs due to its posttranscriptional regulatory mechanisms. A recent investigation of the multiple functions of HuR has provided emerging evidence of its role in drug resistance in various tumors. Herein, we demonstrate the roles of HuR proteins in the development of drug resistance, examine their involvement in various mechanisms, including apoptosis, the ABC transporter family, the cell cycle and the DNA damage response, and provide insight into ongoing studies for developing therapeutic strategies aimed at targeting this molecule in tumor cells.

Entities:  

Keywords:  Drug therapy; HuR; Multidrug-resistant; Neoplasms; RNA-binding proteins

Year:  2019        PMID: 30612309     DOI: 10.1007/s10637-018-00723-x

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  81 in total

Review 1.  Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions.

Authors:  D D'Amours; S Desnoyers; I D'Silva; G G Poirier
Journal:  Biochem J       Date:  1999-09-01       Impact factor: 3.857

2.  Micellar Delivery of miR-34a Modulator Rubone and Paclitaxel in Resistant Prostate Cancer.

Authors:  Di Wen; Yang Peng; Feng Lin; Rakesh K Singh; Ram I Mahato
Journal:  Cancer Res       Date:  2017-04-20       Impact factor: 12.701

3.  The elav gene product of Drosophila, required in neurons, has three RNP consensus motifs.

Authors:  S Robinow; A R Campos; K M Yao; K White
Journal:  Science       Date:  1988-12-16       Impact factor: 47.728

4.  BCL-2 family proteins modulate radiosensitivity in human malignant glioma cells.

Authors:  Johannes R Streffer; Andreas Rimner; Johannes Rieger; Ulrike Naumann; Hans-Peter Rodemann; Michael Weller
Journal:  J Neurooncol       Date:  2002-01       Impact factor: 4.130

5.  Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.

Authors:  Kenneth K W To; W W Leung; Simon S M Ng
Journal:  Exp Cell Res       Date:  2015-09-18       Impact factor: 3.905

6.  HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells.

Authors:  Shruti Lal; Richard A Burkhart; Neil Beeharry; Vikram Bhattacharjee; Eric R Londin; Joseph A Cozzitorto; Carmella Romeo; Masaya Jimbo; Zoë A Norris; Charles J Yeo; Janet A Sawicki; Jordan M Winter; Isidore Rigoutsos; Timothy J Yen; Jonathan R Brody
Journal:  Cancer Res       Date:  2014-02-15       Impact factor: 12.701

7.  Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/GATA3 axis.

Authors:  Bin Li; Xunbo Jin; Huilin Meng; Bo Hu; Tao Zhang; Jiang Yu; Shaoan Chen; Xudong Guo; Weiguo Wang; Wei Jiang; Jin Wang
Journal:  Oncotarget       Date:  2017-07-18

8.  RNPC1 modulates the RNA-binding activity of, and cooperates with, HuR to regulate p21 mRNA stability.

Authors:  Seong Jun Cho; Jin Zhang; Xinbin Chen
Journal:  Nucleic Acids Res       Date:  2010-01-11       Impact factor: 16.971

9.  miRBase: tools for microRNA genomics.

Authors:  Sam Griffiths-Jones; Harpreet Kaur Saini; Stijn van Dongen; Anton J Enright
Journal:  Nucleic Acids Res       Date:  2007-11-08       Impact factor: 16.971

10.  Inhibition of IRES-dependent translation of caspase-2 by HuR confers chemotherapeutic drug resistance in colon carcinoma cells.

Authors:  Amel Badawi; Abhiruchi Biyanee; Usman Nasrullah; Sofia Winslow; Tobias Schmid; Josef Pfeilschifter; Wolfgang Eberhardt
Journal:  Oncotarget       Date:  2018-04-06
View more
  2 in total

Review 1.  Drug delivery approaches for HuR-targeted therapy for lung cancer.

Authors:  Rajeswari Raguraman; Santny Shanmugarama; Meghna Mehta; Jo Elle Peterson; Yan D Zhao; Anupama Munshi; Rajagopal Ramesh
Journal:  Adv Drug Deliv Rev       Date:  2021-11-22       Impact factor: 15.470

Review 2.  Inhibition of Caspase-2 Translation by the mRNA Binding Protein HuR: A Novel Path of Therapy Resistance in Colon Carcinoma Cells?

Authors:  Wolfgang Eberhardt; Usman Nasrullah; Kristina Haeussler
Journal:  Cells       Date:  2019-07-30       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.